Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCD | Q05655 | 13/20 | 0.56 |
| ▸ | PRKCH | P24723 | 13/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 13/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 11/20 | 0.56 |
| ▸ | PRKCA | P17252 | 9/20 | 0.56 |
| ▸ | PRKCB | P05771 | 7/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.54 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.54 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | LATS1 | O95835 | 6/20 | 0.49 |
| ▸ | LATS2 | Q9NRM7 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424433 | 0.85 | IDO1 (0.46) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL1424483 | 0.82 | PRKCD (0.62) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL3325621 | 0.80 | PRKCD (0.52) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL11374306 | 0.80 | PRKCD (0.56) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL31375795 | 0.80 | PRKCD (0.56) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL5798814 | 0.76 | IMPDH2 (0.50) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL20547432 | 0.75 | LATS1 (0.56) | LATS1LATS2 | |
| SCHEMBL29650673 | 0.74 | PRKCD (0.51) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL3324615 | 0.74 | PRKCD (0.51) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL28782749 | 0.74 | PRKCD (0.54) | PRKCDPRKCHPRKCEPRKCQPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | VAN EIS MAURICE | 2010-05-27 | — | — | US | disclosed |
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | VAN EIS MAURICE | 2010-05-27 | — | — | US | disclosed |
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | VAN EIS MAURICE | 2010-05-27 | — | — | US | disclosed |
| CN-101679424-A | As 2 of protein kinase modulators, the 6-7-naphthyridine derivatives | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2144908-A1 | 2, 6-NAPHTHYRIDINE DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis Ag (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008122614-A1 | 2, 6-NAPHTHYRIDINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122614-A1 | 2, 6-NAPHTHYRIDINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | PKN1, PKN2, CDK9 | PRKCD 63/4885PRKCH 22/4885PRKCE 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.